RECARDIO – Regenerative Cardiac Therapy
RECARDIO (REgenerative CARDIOvascular Therapy) is a clinical-stage life science company founded in 2011 and focusing on drug based regenerative therapies for cardiovascular diseases.
The company is located in San Francisco, California, and is having its operations in USA and Europe.
The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company has initiated a Phase 1/2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival.